Executive Summary: A New Era for European Operating Theatres
Globus Medical, a global leader in musculoskeletal implant technology, has officially secured the CE mark for its flagship Excelsius3D imaging system. This regulatory milestone marks a pivotal transition for the company, granting it the authorization to begin commercial distribution across the European Union and the United Kingdom. By merging 3D cone-beam computed tomography (CT), 2D fluoroscopy, and digital radiography into a single, mobile unit, the platform is poised to redefine the standards of intraoperative imaging.
The Excelsius3D system is not merely an imaging device; it is a critical component of the broader "Excelsius Ecosystem." Its introduction to the European market allows surgeons to synchronize advanced imaging with the company’s renowned ExcelsiusGPS robotic navigation system, creating a unified, highly precise workflow that promises to improve patient outcomes in complex spinal and orthopedic surgeries.
The Core Technology: Multimodal Imaging in a Compact Footprint
The primary challenge in modern operating theatres is the clutter of equipment and the time-consuming nature of shifting between different imaging modalities. The Excelsius3D system addresses these logistical hurdles by consolidating three distinct imaging functions into one platform.
1. Advanced Modality Integration
- 3D Cone-Beam CT: Provides high-resolution volumetric images, allowing surgeons to visualize complex anatomy with exceptional clarity during the procedure.
- 2D Fluoroscopy: Offers real-time, dynamic X-ray imaging, essential for guiding instruments and implants during minimally invasive surgery.
- Digital Radiography: Enables high-quality static images for verification and documentation purposes.
2. Design and Ergonomics
Beyond the imaging capabilities, the system’s physical design addresses the constraints of the modern surgical suite. Featuring a compact footprint and multidirectional wheels, the Excelsius3D is engineered for rapid, effortless positioning. This mobility is critical in high-pressure surgical environments where every second counts and space is often at a premium. By streamlining the movement of equipment, Globus Medical aims to reduce "set-up time," effectively increasing the efficiency of the operating room (OR).
Chronology: From FDA Clearance to European Expansion
The path to the European market has been a strategic, multi-year progression for Globus Medical.
- 2021: The US Foundation: The Excelsius3D system first gained significant traction following its 510(k) clearance from the US Food and Drug Administration (FDA). This initial approval validated the safety and efficacy of the platform in the American market, where it has since been integrated into numerous leading hospitals.
- 2024–2025: Strengthening the Portfolio: Recognizing the need to be a holistic player in the surgical tech space, Globus Medical embarked on aggressive strategic growth. In February 2025, the company announced its acquisition of Nevro, a specialist in spinal cord stimulation, for $250 million. This acquisition, finalized in April 2025, significantly bolstered the company’s presence in the neuromodulation sector, setting the stage for a more comprehensive service offering.
- September 2026: European Authorization: The granting of the CE mark acts as the final gateway, confirming that the device meets the stringent health, safety, and environmental protection standards required for products sold within the European Economic Area. This marks the commencement of the commercialization phase for the EU and UK markets.
Supporting Data and Clinical Application
The Excelsius3D platform is indicated for use in both adult and pediatric populations, reflecting the versatility of its imaging sensors. Because the platform is designed to produce images that are natively compatible with the ExcelsiusGPS robotic navigation system, it eliminates the "data gap" that often occurs when using third-party imaging equipment.
When integrated, the robotic arm of the ExcelsiusGPS can utilize the 3D map generated by the Excelsius3D in real-time. This reduces the need for repeated manual adjustments and minimizes the radiation exposure for both the surgical staff and the patient, as the robot can precisely align instruments based on the initial high-fidelity scan.
The system’s ability to function as a standalone unit or as a synchronized robotic assistant provides surgical teams with the flexibility to choose the level of technology required for each specific patient case, whether it is a routine spinal decompression or a complex reconstructive procedure.
Official Responses: A Strategic Milestone
The leadership team at Globus Medical has framed this development as a key pillar of their global strategy. Keith Pfeil, President and CEO of Globus Medical, highlighted the importance of this regulatory achievement during the announcement.
"The CE mark for Excelsius3D represents an important milestone in the continued expansion of the Excelsius Ecosystem," Pfeil noted. "We are committed to bringing innovative enabling technologies to surgeons around the world, and this important milestone further expands the capabilities of our platform by combining intraoperative imaging with the robotic navigation capabilities of ExcelsiusGPS across the European Union."
The sentiment reflects the company’s broader philosophy: that technology should not be viewed as disparate components, but as a cohesive ecosystem that supports the surgeon from the pre-operative planning phase through to the final closure of the incision.
Implications for the Surgical Industry
The arrival of Excelsius3D in the EU and UK markets carries several significant implications for healthcare providers, surgeons, and the medical device industry at large.
1. Competitive Landscape
The imaging-plus-robotics market is highly competitive, with major players such as Medtronic and Stryker holding significant market share. Globus Medical’s ability to offer a proprietary, end-to-end ecosystem gives them a distinct advantage. By controlling both the imaging hardware and the navigation software, they offer a "plug-and-play" experience that is difficult for competitors using fragmented, third-party imaging setups to replicate.
2. Economic Impact on Hospitals
For hospital administrators, the value proposition lies in the reduction of OR time. An efficient, mobile system that reduces the need for external imaging specialists or cumbersome equipment transport can lead to a higher volume of surgeries per day. As healthcare systems in Europe face increasing pressure to reduce wait times and improve throughput, the adoption of efficient, multi-modal platforms like Excelsius3D becomes a necessity rather than a luxury.
3. Patient Outcomes and Safety
The shift toward more robotic-assisted, image-guided procedures is driven primarily by the need for accuracy. The precision offered by the Excelsius Ecosystem significantly reduces the likelihood of "revision surgeries"—procedures necessitated by suboptimal initial implant placement. By providing surgeons with 3D visualization that is perfectly registered to the robotic navigation arm, Globus Medical is helping to lower the margin for human error.
4. Expansion into Neuromodulation and Beyond
With the recent acquisition of Nevro, Globus Medical is not just selling imaging systems; they are selling comprehensive spinal health solutions. The integration of Excelsius3D into this broader portfolio suggests that the company is preparing for a future where imaging, robotics, and neuromodulation are inextricably linked. Surgeons may soon be able to use these platforms to not only place hardware but to perform complex neuro-interventions with a level of precision that was previously impossible.
Conclusion: The Path Ahead
The CE marking of the Excelsius3D platform is more than just a regulatory formality; it is a signal of Globus Medical’s commitment to the European surgical market. As the company begins its commercial rollout, the focus will likely shift toward training, implementation, and gathering clinical data from European centers of excellence.
As surgical technology continues to evolve, the distinction between "imaging" and "navigation" is rapidly disappearing. Globus Medical is positioning itself at the forefront of this convergence. By providing a platform that is compact, mobile, and highly integrated, the company is equipping European surgeons with the tools necessary to meet the demands of modern medicine—ensuring that the next generation of surgery is safer, faster, and more precise than ever before.
As we look toward the remainder of 2026 and into 2027, the industry will be watching to see how the Excelsius Ecosystem changes the standard of care across the continent, potentially setting a new benchmark for how integrated surgical platforms are evaluated and adopted in the global medical device market.
About the Author
